{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:55:32Z","timestamp":1793498132999,"version":"4.5.0"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41574-024-01024-5","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:02:16Z","timestamp":1723712536000},"page":"729-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3135","authenticated-orcid":false,"given":"Ruth T.","family":"Casey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheri","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Waguespack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Wiegering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-1869","authenticated-orcid":false,"given":"Antje","family":"Redlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Akker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathi","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-0368","authenticated-orcid":false,"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-4276","authenticated-orcid":false,"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-2536","authenticated-orcid":false,"given":"Stefan","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Charmandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Chrisoulidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Curr\u00e1s","family":"Freixes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"de Krijger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"de Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol J.","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Kosmoliaptsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kuhlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-2491","authenticated-orcid":false,"given":"Marco","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lussey-Lepoutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Parasiliti-Caprino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri H.J.L.M.","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-5711","authenticated-orcid":false,"given":"Anna Lena","family":"Zietlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6256-5902","authenticated-orcid":false,"given":"Mercedes","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-670X","authenticated-orcid":false,"given":"Anne-Paule","family":"Gimenez-Roqueplo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":false,"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn R.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques W. M.","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Eisenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":false,"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-1604","authenticated-orcid":false,"given":"Christina","family":"Pamporaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/ERC-13-0415","volume":"21","author":"B Bausch","year":"2014","unstructured":"Bausch, B. et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr. Relat. Cancer 21, 17\u201325 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/jpsu.2001.21612","volume":"36","author":"AO Ciftci","year":"2001","unstructured":"Ciftci, A. O., Tanyel, F. C., \u015eenocak, M. E. & B\u00fcy\u00fckpamuk\u00e7u, N. Pheochromocytoma in children. J. Pediatr. Surg. 36, 447\u2013452 (2001).","journal-title":"J. Pediatr. Surg."},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/0002-9610(60)90141-0","volume":"99","author":"DM Hume","year":"1960","unstructured":"Hume, D. M. Pheochromocytoma in the adult and in the child. Am. J. Surg. 99, 458\u2013496 (1960).","journal-title":"Am. J. Surg."},{"key":"1024_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1651-2227.1992.tb12213.x","volume":"81","author":"T Wyszy\u0144ska","year":"1992","unstructured":"Wyszy\u0144ska, T., Cichocka, E., Wieteska\u2010Klimczak, A., Jobs, K. & Januszewicz, P. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr. 81, 244\u2013246 (1992).","journal-title":"Acta Paediatr."},{"key":"1024_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1196\/annals.1353.003","volume":"1073","author":"M Barontini","year":"2006","unstructured":"Barontini, M., Levin, G. & Sanso, G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann. N. Y. Acad. Sci. 1073, 30\u201337 (2006).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2016-3829","volume":"102","author":"C Pamporaki","year":"2017","unstructured":"Pamporaki, C. et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 102, 1122\u20131132 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HPH Neumann","year":"2002","unstructured":"Neumann, H. P. H. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459\u20131466 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR8","doi-asserted-by":"publisher","first-page":"bvaa039","DOI":"10.1210\/jendso\/bvaa039","volume":"4","author":"M de Tersant","year":"2020","unstructured":"de Tersant, M. et al. Pheochromocytoma and paraganglioma in children and adolescents: experience of the French Society of Pediatric Oncology (SFCE). J. Endocr. Soc. 4, bvaa039 (2020).","journal-title":"J. Endocr. Soc."},{"key":"1024_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28981","volume":"68","author":"A Redlich","year":"2021","unstructured":"Redlich, A. et al. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children. Pediatr. Blood Cancer 68, e28981 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein, L. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181\u2013193 (2017).","journal-title":"Cancer Cell"},{"key":"1024_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PLM Dahia","year":"2014","unstructured":"Dahia, P. L. M. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat. Rev. Cancer 14, 108\u2013119 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4158\/EP161377.OR","volume":"23","author":"I Micha\u0142owska","year":"2017","unstructured":"Micha\u0142owska, I. et al. Growth rate of paragangliomas related to germline mutations of the SDHx genes. Endocr. Pract. 23, 342\u2013352 (2017).","journal-title":"Endocr. Pract."},{"key":"1024_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1542\/peds.2005-2299","volume":"118","author":"TH Pham","year":"2006","unstructured":"Pham, T. H. et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 118, 1109\u20131117 (2006).","journal-title":"Pediatrics"},{"key":"1024_CR14","doi-asserted-by":"publisher","first-page":"e1907","DOI":"10.1210\/clinem\/dgac019","volume":"107","author":"DF Davidoff","year":"2022","unstructured":"Davidoff, D. F. et al. Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study. J. Clin. Endocrinol. Metab. 107, e1907\u2013e1916 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","volume":"17","author":"L Amar","year":"2021","unstructured":"Amar, L. et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat. Rev. Endocrinol. 17, 435\u2013444 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1024_CR16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins, D. et al. Grading quality of evidence and strength of recommendations. BMJ 328, 1490 (2004).","journal-title":"BMJ"},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1210\/jc.2007-1907","volume":"93","author":"BA Swiglo","year":"2008","unstructured":"Swiglo, B. A. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93, 666\u2013673 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR18","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht, M. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1476\u20131490 (2020).","journal-title":"Ann. Oncol."},{"key":"1024_CR19","unstructured":"PDQ Pediatric Treatment Editorial Board. Childhood pheochromocytoma and paraganglioma treatment (PDQ\u00ae): health professional version. In PDQ Cancer Information Summaries (National Cancer Institute, 2022)."},{"key":"1024_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JWM Lenders","year":"2014","unstructured":"Lenders, J. W. M. et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915\u20131942 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3747\/co.19.944","volume":"19","author":"JM Croke","year":"2012","unstructured":"Croke, J. M. & El-Sayed, S. Multidisciplinary management of cancer patients: chasing a shadow or real value? An overview of the literature. Curr. Oncol. 19, 232\u2013238 (2012).","journal-title":"Curr. Oncol."},{"key":"1024_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/jcm8060910","volume":"8","author":"L Magi","year":"2019","unstructured":"Magi, L. et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J. Clin. Med. 8, 910 (2019).","journal-title":"J. Clin. Med."},{"key":"1024_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/MED.0b013e32835570f1","volume":"19","author":"DC Metz","year":"2012","unstructured":"Metz, D. C. et al. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr. Opin. Endocrinol. Diabetes Obes. 19, 306\u2013313 (2012).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"1024_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","volume":"11","author":"D Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb, D. et al. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 11, 345\u2013361 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1024_CR25","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/0022-3468(92)90396-O","volume":"27","author":"Y R\u00e9villon","year":"1992","unstructured":"R\u00e9villon, Y. et al. Pheochromocytoma in children: 15 cases. J. Pediatr. Surg. 27, 910\u2013911 (1992).","journal-title":"J. Pediatr. Surg."},{"key":"1024_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28332","volume":"67","author":"C Virgone","year":"2020","unstructured":"Virgone, C. et al. Pheochromocytomas and paragangliomas in children: data from the Italian Cooperative Study (TREP). Pediatr. Blood Cancer 67, e28332 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1530\/EJE-19-0159","volume":"181","author":"A Geroula","year":"2019","unstructured":"Geroula, A. et al. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur. J. Endocrinol. 181, 409\u2013420 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"1024_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12020-010-9319-3","volume":"37","author":"KS King","year":"2010","unstructured":"King, K. S., Darmani, N. A., Hughes, M. S., Adams, K. T. & Pacak, K. Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. Endocrine 37, 403\u2013407 (2010).","journal-title":"Endocrine"},{"key":"1024_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1055\/s-0042-106725","volume":"48","author":"M Batsis","year":"2016","unstructured":"Batsis, M. et al. Attention deficit hyperactivity disorder in pediatric patients with pheochromocytoma and paraganglioma. Horm. Metab. Res. 48, 509\u2013513 (2016).","journal-title":"Horm. Metab. Res."},{"key":"1024_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/000992280504400811","volume":"44","author":"J Sullivan","year":"2005","unstructured":"Sullivan, J., Groshong, T. & Tobias, J. D. Presenting signs and symptoms of pheochromocytoma in pediatric-aged patients. Clin. Pediatr. 44, 715\u2013719 (2005).","journal-title":"Clin. Pediatr."},{"key":"1024_CR31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn, J. T. et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140, e20171904 (2017).","journal-title":"Pediatrics"},{"key":"1024_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00467-011-1964-0","volume":"27","author":"J Chandar","year":"2012","unstructured":"Chandar, J. & Zilleruelo, G. Hypertensive crisis in children. Pediatr. Nephrol. 27, 741\u2013751 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"1024_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"Lenders, J. W., Eisenhofer, G., Mannelli, M. & Pacak, K. Phaeochromocytoma. Lancet 366, 665\u2013675 (2005).","journal-title":"Lancet"},{"key":"1024_CR34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/000313480006601201","volume":"66","author":"VS Reddy","year":"2000","unstructured":"Reddy, V. S. et al. Twenty-five-year surgical experience with pheochromocytoma in children. Am. Surg. 66, 1085\u20131091 (2000).","journal-title":"Am. Surg."},{"key":"1024_CR35","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJM199906173402404","volume":"340","author":"G Eisenhofer","year":"1999","unstructured":"Eisenhofer, G. et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel\u2013Lindau disease and multiple endocrine neoplasia type 2. N. Engl. J. Med. 340, 1872\u20131879 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR36","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","volume":"64","author":"G Eisenhofer","year":"2018","unstructured":"Eisenhofer, G. et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites. Clin. Chem. 64, 1646\u20131656 (2018).","journal-title":"Clin. Chem."},{"key":"1024_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2125.1981.tb01210.x","volume":"12","author":"MJ Brown","year":"1981","unstructured":"Brown, M. J. & Allison, D. J. Renal conversion of plasma DOPA to urine dopamine. Br. J. Clin. Pharmacol. 12, 251\u2013253 (1981).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1024_CR38","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.clinbiochem.2016.05.008","volume":"49","author":"F Patin","year":"2016","unstructured":"Patin, F. et al. Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas. Clin. Biochem. 49, 1205\u20131208 (2016).","journal-title":"Clin. Biochem."},{"key":"1024_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-1016","volume":"182","author":"M Peitzsch","year":"2020","unstructured":"Peitzsch, M. et al. Overnight\/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option? Eur. J. Endocrinol. 182, 499\u2013509 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"1024_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cca.2017.12.026","volume":"478","author":"M Zuo","year":"2018","unstructured":"Zuo, M. et al. High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection. Clin. Chim. Acta 478, 82\u201389 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"1024_CR41","doi-asserted-by":"publisher","first-page":"101346","DOI":"10.1016\/j.beem.2019.101346","volume":"34","author":"E Sbardella","year":"2020","unstructured":"Sbardella, E. & Grossman, A. B. Pheochromocytoma: an approach to diagnosis. Best. Pract. Res. Clin. Endocrinol. Metab. 34, 101346 (2020).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"1024_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12020-020-02267-8","volume":"69","author":"K Wang","year":"2020","unstructured":"Wang, K. et al. Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma. Endocrine 69, 188\u2013195 (2020).","journal-title":"Endocrine"},{"key":"1024_CR43","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4158\/EP12050.OR","volume":"18","author":"V Sarathi","year":"2012","unstructured":"Sarathi, V. et al. Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma in children. Endocr. Pract. 18, 694\u2013699 (2012).","journal-title":"Endocr. Pract."},{"key":"1024_CR44","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1210\/jcem.87.5.8446","volume":"87","author":"M Weise","year":"2002","unstructured":"Weise, M., Merke, D. P., Pacak, K., Walther, M. M. & Eisenhofer, G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J. Clin. Endocrinol. Metab. 87, 1955\u20131960 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/clinchem\/39.1.97","volume":"39","author":"JW Lenders","year":"1993","unstructured":"Lenders, J. W. et al. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin. Chem. 39, 97\u2013103 (1993).","journal-title":"Clin. Chem."},{"key":"1024_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1258\/acb.2012.012112","volume":"50","author":"M Peitzsch","year":"2013","unstructured":"Peitzsch, M. et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann. Clin. Biochem. 50, 147\u2013155 (2013).","journal-title":"Ann. Clin. Biochem."},{"key":"1024_CR47","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-14-0730","volume":"172","author":"D Weismann","year":"2015","unstructured":"Weismann, D. et al. Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. Eur. J. Endocrinol. 172, 251\u2013260 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"1024_CR48","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/endrev\/bnad011","volume":"44","author":"G Eisenhofer","year":"2023","unstructured":"Eisenhofer, G., Pamporaki, C. & Lenders, J. W. M. Biochemical assessment of pheochromocytoma and paraganglioma. Endocr. Rev. 44, 862\u2013909 (2023).","journal-title":"Endocr. Rev."},{"key":"1024_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/01.CIR.59.4.637","volume":"59","author":"D Robertson","year":"1979","unstructured":"Robertson, D. et al. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 59, 637\u2013643 (1979).","journal-title":"Circulation"},{"key":"1024_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2265.2009.03761.x","volume":"73","author":"T Deutschbein","year":"2010","unstructured":"Deutschbein, T. et al. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clin. Endocrinol. 73, 153\u2013160 (2010).","journal-title":"Clin. Endocrinol."},{"key":"1024_CR51","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/cen.12327","volume":"80","author":"R D\u00e4rr","year":"2014","unstructured":"D\u00e4rr, R. et al. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin. Endocrinol. 80, 478\u2013486 (2014).","journal-title":"Clin. Endocrinol."},{"key":"1024_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/EJE-19-0176","volume":"181","author":"J Boyd","year":"2019","unstructured":"Boyd, J. et al. A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. Eur. J. Endocrinol. 181, 301\u2013309 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"1024_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/NAN.0000000000000184","volume":"39","author":"LS Cook","year":"2016","unstructured":"Cook, L. S. Needle phobia. J. Infus. Nurs. 39, 273\u2013279 (2016).","journal-title":"J. Infus. Nurs."},{"key":"1024_CR54","first-page":"727","volume":"3","author":"P Netter","year":"1987","unstructured":"Netter, P. Psychological aspects of catecholamine response patterns to pain and mental stress in essential hypertensive patients and controls. J. Clin. Hypertens. 3, 727\u2013742 (1987).","journal-title":"J. Clin. Hypertens."},{"key":"1024_CR55","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1515\/cclm-2020-0022","volume":"58","author":"K Eijkelenkamp","year":"2020","unstructured":"Eijkelenkamp, K. et al. Blood sampling for metanephrines comparing venipuncture vs. indwelling intravenous cannula in healthy subjects. Clin. Chem. Lab. Med. 58, 1681\u20131686 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"1024_CR56","doi-asserted-by":"publisher","first-page":"e3689","DOI":"10.1210\/clinem\/dgac390","volume":"107","author":"G Pommer","year":"2022","unstructured":"Pommer, G. et al. Preanalytical considerations and outpatient versus inpatient tests of plasma metanephrines to diagnose pheochromocytoma. J. Clin. Endocrinol. Metab. 107, e3689\u2013e3698 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR57","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1542\/peds.2009-2920","volume":"126","author":"S Berger-Achituv","year":"2010","unstructured":"Berger-Achituv, S., Budde-Schwartzman, B., Ellis, M. H., Shenkman, Z. & Erez, I. Blood sampling through peripheral venous catheters is reliable for selected basic analytes in children. Pediatrics 126, e179\u2013e186 (2010).","journal-title":"Pediatrics"},{"key":"1024_CR58","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1129729819865709","volume":"21","author":"SU Lee","year":"2020","unstructured":"Lee, S. U. et al. Factors associated with difficult intravenous access in the pediatric emergency department. J. Vasc. Access. 21, 180\u2013185 (2020).","journal-title":"J. Vasc. Access."},{"key":"1024_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/1054773816686262","volume":"27","author":"H-C Kuo","year":"2018","unstructured":"Kuo, H.-C., Pan, H.-H., Creedy, D. K. & Tsao, Y. Distraction-based interventions for children undergoing venipuncture procedures: a randomized controlled study. Clin. Nurs. Res. 27, 467\u2013482 (2018).","journal-title":"Clin. Nurs. Res."},{"key":"1024_CR60","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-13-0673","volume":"170","author":"C Pamporaki","year":"2014","unstructured":"Pamporaki, C. et al. Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Eur. J. Endocrinol. 170, 349\u2013357 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"1024_CR61","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1210\/jc.2009-0303","volume":"94","author":"WHA de Jong","year":"2009","unstructured":"de Jong, W. H. A. et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J. Clin. Endocrinol. Metab. 94, 2841\u20132849 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR62","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1210\/jcem.84.7.5864","volume":"84","author":"DS Goldstein","year":"1999","unstructured":"Goldstein, D. S. et al. Sources and physiological significance of plasma dopamine sulfate. J. Clin. Endocrinol. Metab. 84, 2523\u20132531 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1042\/cs0880533","volume":"88","author":"G Eisenhofer","year":"1995","unstructured":"Eisenhofer, G. et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin. Sci. 88, 533\u2013542 (1995).","journal-title":"Clin. Sci."},{"key":"1024_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2362.1970.tb00600.x","volume":"1","author":"E J\u00e9quier","year":"1970","unstructured":"J\u00e9quier, E. & Perret, C. Urinary excretion of catecholamines and their main metabolites after myocardial infarction; relationahip to the clinical syndrome. Eur. J. Clin. Invest. 1, 77\u201383 (1970).","journal-title":"Eur. J. Clin. Invest."},{"key":"1024_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/jcp.2006.036640","volume":"60","author":"MKS Leow","year":"2007","unstructured":"Leow, M. K. S., Loh, K. C., Kiat Kwek, T. & Ng, P. Y. Catecholamine and metanephrine excess in intracerebral haemorrhage: revisiting an obscure yet common \u2018pseudophaeochromocytoma\u2019. J. Clin. Pathol. 60, 583\u2013584 (2007).","journal-title":"J. Clin. Pathol."},{"key":"1024_CR66","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jcp.2003.013201","volume":"57","author":"AA Syed","year":"2004","unstructured":"Syed, A. A., Wheatley, H. A., Badminton, M. N. & McDowell, I. F. W. Urinary catecholamines and metabolites in the immediate postoperative period following major surgery. J. Clin. Pathol. 57, 548\u2013550 (2004).","journal-title":"J. Clin. Pathol."},{"key":"1024_CR67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jns.2006.10.001","volume":"252","author":"A Chamorro","year":"2007","unstructured":"Chamorro, A. et al. Catecholamines, infection, and death in acute ischemic stroke. J. Neurol. Sci. 252, 29\u201335 (2007).","journal-title":"J. Neurol. Sci."},{"key":"1024_CR68","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.amjmed.2021.03.015","volume":"134","author":"GA Kline","year":"2021","unstructured":"Kline, G. A., Boyd, J., Sadrzadeh, H. S. M. & Leung, A. A. Inpatient measurements of urine metanephrines are indistinguishable from pheochromocytoma: retrospective cohort study. Am. J. Med. 134, 1039\u20131046.e3 (2021).","journal-title":"Am. J. Med."},{"key":"1024_CR69","doi-asserted-by":"crossref","unstructured":"Eisenhofer, G., Januszewicz, A., Pamporaki, C., Lenders, J. W. M. in Endocrine and Metabolic Medical Emergencies. A Clinician\u2019s Guide 2nd edn Ch. 22 (ed. Matfin, G.) 355\u2013374 (Wiley, 2018).","DOI":"10.1002\/9781119374800.ch22"},{"key":"1024_CR70","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cca.2019.03.1620","volume":"494","author":"M Peitzsch","year":"2019","unstructured":"Peitzsch, M., Mangelis, A., Eisenhofer, G. & Huebner, A. Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: particular importance for early infancy. Clin. Chim. Acta 494, 100\u2013105 (2019).","journal-title":"Clin. Chim. Acta"},{"key":"1024_CR71","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/pbc.25385","volume":"62","author":"LC Franscini","year":"2015","unstructured":"Franscini, L. C. et al. Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma. Pediatr. Blood Cancer 62, 587\u2013593 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR72","doi-asserted-by":"publisher","first-page":"901760","DOI":"10.3389\/fendo.2022.901760","volume":"13","author":"G Eisenhofer","year":"2022","unstructured":"Eisenhofer, G., Peitzsch, M., Bechmann, N. & Huebner, A. Biochemical diagnosis of catecholamine-producing tumors of childhood: neuroblastoma, pheochromocytoma and paraganglioma. Front. Endocrinol. 13, 901760 (2022).","journal-title":"Front. Endocrinol."},{"key":"1024_CR73","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1651-2227.1990.tb11404.x","volume":"79","author":"N Modi","year":"1990","unstructured":"Modi, N. & Hutton, J. L. Urinary creatinine excretion and estimation of muscle mass in infants of 25\u201034 weeks gestation. Acta Paediatr. 79, 1156\u20131162 (1990).","journal-title":"Acta Paediatr."},{"key":"1024_CR74","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/adc.63.4.398","volume":"63","author":"J Al-Dahhan","year":"1988","unstructured":"Al-Dahhan, J., Stimmler, L., Chantler, C. & Haycock, G. B. Urinary creatinine excretion in the newborn. Arch. Dis. Child. 63, 398\u2013402 (1988).","journal-title":"Arch. Dis. Child."},{"key":"1024_CR75","first-page":"596","volume":"155","author":"AM Skinner","year":"1996","unstructured":"Skinner, A. M., Addison, G. M. & Price, D. A. Changes in the urinary excretion of creatinine, albumin and N-acetyl-\u03b2-D-glucosaminidase with increasing age and maturity in healthy schoolchildren. Eur. J. Pediatr. 155, 596\u2013602 (1996).","journal-title":"Eur. J. Pediatr."},{"key":"1024_CR76","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.clinbiochem.2008.10.022","volume":"42","author":"E Pussard","year":"2009","unstructured":"Pussard, E., Neveux, M. & Guigueno, N. Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin. Biochem. 42, 536\u2013539 (2009).","journal-title":"Clin. Biochem."},{"key":"1024_CR77","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1258\/acb.2010.010062","volume":"48","author":"A Griffin","year":"2011","unstructured":"Griffin, A., O\u2019Shea, P., FitzGerald, R., O\u2019Connor, G. & Tormey, W. Establishment of a paediatric age-related reference interval for the measurement of urinary total fractionated metanephrines. Ann. Clin. Biochem. Int. J. Lab. Med. 48, 41\u201344 (2011).","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"1024_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/000456329403100101","volume":"31","author":"MC Fitzgibbon","year":"1994","unstructured":"Fitzgibbon, M. C. & Tormey, W. P. Paediatric reference ranges for urinary catecholamines\/metabolites and their relevance in neuroblastoma diagnosis. Ann. Clin. Biochem. Int. J. Lab. Med. 31, 1\u201311 (1994).","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"1024_CR79","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cca.2018.12.019","volume":"490","author":"G Eisenhofer","year":"2019","unstructured":"Eisenhofer, G. et al. Reference intervals for LC-MS\/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clin. Chim. Acta 490, 46\u201354 (2019).","journal-title":"Clin. Chim. Acta"},{"key":"1024_CR80","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1055\/a-0926-3532","volume":"51","author":"M Haap","year":"2019","unstructured":"Haap, M., Blaschka, F., Lehmann, R., Hoyer, A. & M\u00fcssig, K. Association between urinary catecholamine excretion and urine volume. Horm. Metab. Res. 51, 531\u2013538 (2019).","journal-title":"Horm. Metab. Res."},{"key":"1024_CR81","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1258\/acb.2011.011023","volume":"48","author":"DF Davidson","year":"2011","unstructured":"Davidson, D. F., Hammond, P. J., Murphy, D. & Carachi, R. Age-related medical decision limits for urinary free (unconjugated) metadrenalines, catecholamines and metabolites in random urine specimens from children. Ann. Clin. Biochem. Int. J. Lab. Med. 48, 358\u2013366 (2011).","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"1024_CR82","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/jch.13657","volume":"21","author":"D Hirsch","year":"2019","unstructured":"Hirsch, D., Grossman, A., Nadler, V., Alboim, S. & Tsvetov, G. Pheochromocytoma: positive predictive values of mildly elevated urinary fractionated metanephrines in a large cohort of community-dwelling patients. J. Clin. Hypertens. 21, 1527\u20131533 (2019).","journal-title":"J. Clin. Hypertens."},{"key":"1024_CR83","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1210\/jc.2002-030005","volume":"88","author":"G Eisenhofer","year":"2003","unstructured":"Eisenhofer, G. et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab. 88, 2656\u20132666 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR84","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s00261-019-02213-x","volume":"45","author":"AK Hanafy","year":"2020","unstructured":"Hanafy, A. K. et al. Imaging features of adrenal gland masses in the pediatric population. Abdom. Radiol. 45, 964\u2013981 (2020).","journal-title":"Abdom. Radiol."},{"key":"1024_CR85","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1515\/jpem-2016-0080","volume":"30","author":"AF de Melo-Leite","year":"2017","unstructured":"Melo-Leite, de A. F. et al. Adrenocortical neoplasms in adulthood and childhood: distinct presentation. Review of the clinical, pathological and imaging characteristics. J. Pediatr. Endocrinol. Metab. 30, 253\u2013276 (2017).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1024_CR86","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","volume":"229","author":"RE Goldstein","year":"1999","unstructured":"Goldstein, R. E. et al. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229, 755\u2013764 (1999).","journal-title":"Ann. Surg."},{"key":"1024_CR87","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1210\/jc.2003-031091","volume":"89","author":"I Ilias","year":"2004","unstructured":"Ilias, I. & Pacak, K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J. Clin. Endocrinol. Metab. 89, 479\u2013491 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR88","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/EJE-16-0595","volume":"175","author":"E Daniel","year":"2016","unstructured":"Daniel, E., Jones, R., Bull, M. & Newell-Price, J. Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase mutations. Eur. J. Endocrinol. 175, 561\u2013570 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"1024_CR89","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/cen.13980","volume":"91","author":"N Tufton","year":"2019","unstructured":"Tufton, N., White, G., Drake, W. M., Sahdev, A. & Akker, S. A. Diffusion\u2010weighted imaging (DWI) highlights SDHB\u2010related tumours: a pilot study. Clin. Endocrinol. 91, 104\u2013109 (2019).","journal-title":"Clin. Endocrinol."},{"key":"1024_CR90","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/pbc.24533","volume":"60","author":"DA Weiser","year":"2013","unstructured":"Weiser, D. A., Kaste, S. C., Siegel, M. J. & Adamson, P. C. Imaging in childhood cancer: a Society for Pediatric Radiology and Children\u2019s Oncology Group Joint Task Force report. Pediatr. Blood Cancer 60, 1253\u20131260 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR91","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2165\/00002018-200730110-00004","volume":"30","author":"G Eisenhofer","year":"2007","unstructured":"Eisenhofer, G. et al. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug. Saf. 30, 1031\u20131062 (2007).","journal-title":"Drug. Saf."},{"key":"1024_CR92","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pbc.22575","volume":"55","author":"AL Chong","year":"2010","unstructured":"Chong, A. L. et al. Imaging in pediatric patients: time to think again about surveillance. Pediatr. Blood Cancer 55, 407\u2013413 (2010).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR93","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1542\/peds.2009-2675","volume":"126","author":"BA Ahmed","year":"2010","unstructured":"Ahmed, B. A. et al. Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics 126, e851\u2013e858 (2010).","journal-title":"Pediatrics"},{"key":"1024_CR94","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2967\/jnumed.117.195263","volume":"58","author":"JA Siegel","year":"2017","unstructured":"Siegel, J. A., Sacks, B., Pennington, C. W. & Welsh, J. S. Dose optimization to minimize radiation risk for children undergoing CT and nuclear medicine imaging is misguided and detrimental. J. Nucl. Med. 58, 865\u2013868 (2017).","journal-title":"J. Nucl. Med."},{"key":"1024_CR95","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1007\/s00247-008-1026-3","volume":"39","author":"MS Linet","year":"2009","unstructured":"Linet, M. S., Kim, K. P. & Rajaraman, P. Children\u2019s exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr. Radiol. 39, S4\u2013S26 (2009).","journal-title":"Pediatr. Radiol."},{"key":"1024_CR96","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb, D. et al. European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 46, 2112\u20132137 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1024_CR97","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2214\/AJR.21.26071","volume":"218","author":"A Jha","year":"2022","unstructured":"Jha, A. et al. Sporadic primary pheochromocytoma: a prospective intraindividual comparison of six imaging tests (CT, MRI, and PET\/CT using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA). AJR Am. J. Roentgenol. 218, 342\u2013350 (2022).","journal-title":"AJR Am. J. Roentgenol."},{"key":"1024_CR98","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00259-017-3896-9","volume":"45","author":"A Jha","year":"2018","unstructured":"Jha, A. et al. Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur. J. Nucl. Med. Mol. Imaging 45, 787\u2013797 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1024_CR99","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"Janssen, I. et al. Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. 21, 3888\u20133895 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1024_CR100","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnumed.115.161018","volume":"57","author":"I Janssen","year":"2016","unstructured":"Janssen, I. et al. 68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI. J. Nucl. Med. 57, 186\u2013191 (2016).","journal-title":"J. Nucl. Med."},{"key":"1024_CR101","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1515\/jpem-2020-0354","volume":"34","author":"SK Jaiswal","year":"2021","unstructured":"Jaiswal, S. K. et al. The utility of 68Ga-DOTATATE PET\/CT in localizing primary\/metastatic pheochromocytoma and paraganglioma in children and adolescents \u2013 a single-center experience. J. Pediatr. Endocrinol. Metab. 34, 109\u2013119 (2021).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1024_CR102","doi-asserted-by":"publisher","first-page":"109168","DOI":"10.1016\/j.biopha.2019.109168","volume":"117","author":"WT Rahman","year":"2019","unstructured":"Rahman, W. T. et al. The impact of infection and inflammation in oncologic 18F-FDG PET\/CT imaging. Biomed. Pharmacother 117, 109168 (2019).","journal-title":"Biomed. Pharmacother"},{"key":"1024_CR103","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","volume":"25","author":"HJLM Timmers","year":"2007","unstructured":"Timmers, H. J. L. M. et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J. Clin. Oncol. 25, 2262\u20132269 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR104","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1210\/jc.2009-1054","volume":"94","author":"H-B Fiebrich","year":"2009","unstructured":"Fiebrich, H.-B. et al. 6-[F-18]fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J. Clin. Endocrinol. Metab. 94, 3922\u20133930 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR105","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/ERC-11-0243","volume":"19","author":"JS Fonte","year":"2012","unstructured":"Fonte, J. S. et al. False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr. Relat. Cancer 19, 83\u201393 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"1024_CR106","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","volume":"4","author":"I Jochmanova","year":"2018","unstructured":"Jochmanova, I. & Pacak, K. Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer 4, 6\u20139 (2018).","journal-title":"Trends Cancer"},{"key":"1024_CR107","doi-asserted-by":"publisher","first-page":"e1917","DOI":"10.1210\/clinem\/dgac014","volume":"107","author":"C Horton","year":"2022","unstructured":"Horton, C. et al. Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield. J. Clin. Endocrinol. Metab. 107, e1917\u2013e1923 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR108","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1210\/me.2010-0256","volume":"24","author":"E L\u00f3pez-Jim\u00e9nez","year":"2010","unstructured":"L\u00f3pez-Jim\u00e9nez, E. et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol. Endocrinol. 24, 2382\u20132391 (2010).","journal-title":"Mol. Endocrinol."},{"key":"1024_CR109","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/hmg\/dds374","volume":"21","author":"N Burnichon","year":"2012","unstructured":"Burnichon, N. et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum. Mol. Genet. 21, 5397\u20135405 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"1024_CR110","doi-asserted-by":"publisher","first-page":"C13","DOI":"10.1530\/ERC-13-0046","volume":"20","author":"J Welander","year":"2013","unstructured":"Welander, J., S\u00f6derkvist, P. & Gimm, O. The NF1 gene: a frequent mutational target in sporadic pheochromocytomas and beyond. Endocr. Relat. Cancer 20, C13\u2013C17 (2013).","journal-title":"Endocr. Relat. Cancer"},{"key":"1024_CR111","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete, O. et al. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr. Pathol. 33, 90\u2013114 (2022).","journal-title":"Endocr. Pathol."},{"key":"1024_CR112","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jmoldx.2017.04.009","volume":"19","author":"M Curr\u00e1s-Freixes","year":"2017","unstructured":"Curr\u00e1s-Freixes, M. et al. PheoSeq. J. Mol. Diagn. 19, 575\u2013588 (2017).","journal-title":"J. Mol. Diagn."},{"key":"1024_CR113","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1210\/jc.2013-2191","volume":"98","author":"PLM Dahia","year":"2013","unstructured":"Dahia, P. L. M. The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage. J. Clin. Endocrinol. Metab. 98, 2679\u20132681 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR114","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.185","volume":"13","author":"RA Toledo","year":"2017","unstructured":"Toledo, R. A. et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat. Rev. Endocrinol. 13, 233\u2013247 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1024_CR115","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1200\/JCO.2012.47.1912","volume":"31","author":"K Pacak","year":"2013","unstructured":"Pacak, K. et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J. Clin. Oncol. 31, 1690\u20131698 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR116","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s00268-018-4488-y","volume":"42","author":"MK Walz","year":"2018","unstructured":"Walz, M. K. et al. Minimally invasive surgery (MIS) in children and adolescents with pheochromocytomas and retroperitoneal paragangliomas: experiences in 42 patients. World J. Surg. 42, 1024\u20131030 (2018).","journal-title":"World J. Surg."},{"key":"1024_CR117","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jpedsurg.2011.08.003","volume":"47","author":"Y Heloury","year":"2012","unstructured":"Heloury, Y. et al. Minimally invasive adrenalectomy in children. J. Pediatr. Surg. 47, 415\u2013421 (2012).","journal-title":"J. Pediatr. Surg."},{"key":"1024_CR118","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamasurg.2018.2648","volume":"153","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. Risk factors associated with perioperative complications and prolonged length of stay after laparoscopic adrenalectomy. JAMA Surg. 153, 1036 (2018).","journal-title":"JAMA Surg."},{"key":"1024_CR119","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1109\/TBME.1987.325971","volume":"34","author":"AJ Peyton","year":"1987","unstructured":"Peyton, A. J. Circuit for monitoring the median frequency of the spectrum of the surface EMG signal. IEEE Trans. Biomed. Eng. 34, 391\u2013394 (1987).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"1024_CR120","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00464-007-9478-3","volume":"22","author":"MC Takata","year":"2008","unstructured":"Takata, M. C., Kebebew, E., Clark, O. H. & Duh, Q.-Y. Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases. Surg. Endosc. 22, 202\u2013207 (2008).","journal-title":"Surg. Endosc."},{"key":"1024_CR121","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8898","volume":"2","author":"HPH Neumann","year":"2019","unstructured":"Neumann, H. P. H. et al. Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy. JAMA Netw. Open. 2, e198898 (2019).","journal-title":"JAMA Netw. Open."},{"key":"1024_CR122","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00432-020-03138-5","volume":"146","author":"I Jochmanova","year":"2020","unstructured":"Jochmanova, I. et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J. Cancer Res. Clin. Oncol. 146, 1051\u20131063 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1024_CR123","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","volume":"38","author":"JWM Lenders","year":"2020","unstructured":"Lenders, J. W. M. et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 38, 1443\u20131456 (2020).","journal-title":"J. Hypertens."},{"key":"1024_CR124","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip, L. et al. American Association of Endocrine Surgeons guidelines for adrenalectomy. JAMA Surg. 157, 870\u2013877 (2022).","journal-title":"JAMA Surg."},{"key":"1024_CR125","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","volume":"50","author":"L Fishbein","year":"2021","unstructured":"Fishbein, L. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma. Pancreas 50, 469\u2013493 (2021).","journal-title":"Pancreas"},{"key":"1024_CR126","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11906-021-01150-9","volume":"23","author":"ML Seamon","year":"2021","unstructured":"Seamon, M. L. & Yamaguchi, I. Hypertension in pheochromocytoma and paraganglioma: evaluation and management in pediatric patients. Curr. Hypertens. Rep. 23, 32 (2021).","journal-title":"Curr. Hypertens. Rep."},{"key":"1024_CR127","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(10)62226-X","volume":"377","author":"S Fleming","year":"2011","unstructured":"Fleming, S. et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 377, 1011\u20131018 (2011).","journal-title":"Lancet"},{"key":"1024_CR128","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.amjsurg.2007.08.028","volume":"194","author":"AD Ludwig","year":"2007","unstructured":"Ludwig, A. D. et al. Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am. J. Surg. 194, 792\u2013796 (2007).","journal-title":"Am. J. Surg."},{"key":"1024_CR129","doi-asserted-by":"publisher","first-page":"e2393","DOI":"10.1210\/clinem\/dgab130","volume":"106","author":"LM Gruber","year":"2021","unstructured":"Gruber, L. M. et al. The role for metyrosine in the treatment of patients with pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 106, e2393\u2013e2401 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR130","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1055\/s-0035-1555900","volume":"47","author":"T Zelinka","year":"2015","unstructured":"Zelinka, T. et al. Biochemical testing after pheochromocytoma removal: how early? Horm. Metab. Res. 47, 633\u2013636 (2015).","journal-title":"Horm. Metab. Res."},{"key":"1024_CR131","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","volume":"29","author":"KS King","year":"2011","unstructured":"King, K. S. et al. Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J. Clin. Oncol. 29, 4137\u20134142 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR132","doi-asserted-by":"publisher","first-page":"936178","DOI":"10.3389\/fendo.2022.936178","volume":"13","author":"MJM Kuo","year":"2022","unstructured":"Kuo, M. J. M., Nazari, M. A., Jha, A. & Pacak, K. Pediatric metastatic pheochromocytoma and paraganglioma: clinical presentation and diagnosis, genetics, and therapeutic approaches. Front. Endocrinol. 13, 936178 (2022).","journal-title":"Front. Endocrinol."},{"key":"1024_CR133","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgac563","volume":"108","author":"M Li","year":"2023","unstructured":"Li, M. et al. Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 108, 397\u2013404 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR134","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","volume":"91","author":"FR Lorenzo","year":"2013","unstructured":"Lorenzo, F. R. et al. A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J. Mol. Med. 91, 507\u2013512 (2013).","journal-title":"J. Mol. Med."},{"key":"1024_CR135","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJMoa1205119","volume":"367","author":"Z Zhuang","year":"2012","unstructured":"Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922\u2013930 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR136","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0050","volume":"30","author":"JS Rosenblum","year":"2023","unstructured":"Rosenblum, J. S., Wang, H., Nazari, M. A., Zhuang, Z. & Pacak, K. Pacak\u2013Zhuang syndrome: a model providing new insights into tumor syndromes. Endocr. Relat. Cancer 30, e230050 (2023).","journal-title":"Endocr. Relat. Cancer"},{"key":"1024_CR137","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1530\/ERC-16-0231","volume":"23","author":"R D\u00e4rr","year":"2016","unstructured":"D\u00e4rr, R. et al. Novel insights into the polycythemia\u2013paraganglioma\u2013somatostatinoma syndrome. Endocr. Relat. Cancer 23, 899\u2013908 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"1024_CR138","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/cen.14639","volume":"97","author":"B Winzeler","year":"2022","unstructured":"Winzeler, B. et al. Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort. Clin. Endocrinol. 97, 448\u2013459 (2022).","journal-title":"Clin. Endocrinol."},{"key":"1024_CR139","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/cge.12092","volume":"84","author":"P Wu","year":"2013","unstructured":"Wu, P. et al. Mosaicism in von Hippel-Lindau disease with severe renal manifestations. Clin. Genet. 84, 581\u2013584 (2013).","journal-title":"Clin. Genet."},{"key":"1024_CR140","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/ejhg.2013.279","volume":"22","author":"L Coppin","year":"2014","unstructured":"Coppin, L. et al. VHL mosaicism can be detected by clinical next-generation sequencing and is not restricted to patients with a mild phenotype. Eur. J. Hum. Genet. 22, 1149\u20131152 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"1024_CR141","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.amepre.2015.08.031","volume":"50","author":"MJ Khoury","year":"2016","unstructured":"Khoury, M. J., Iademarco, M. F. & Riley, W. T. Precision public health for the era of precision medicine. Am. J. Prev. Med. 50, 398\u2013401 (2016).","journal-title":"Am. J. Prev. Med."},{"key":"1024_CR142","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41436-019-0735-3","volume":"22","author":"EM Bednar","year":"2020","unstructured":"Bednar, E. M., Sun, C. C., McCurdy, S. & Vernon, S. W. Assessing relatives\u2019 readiness for hereditary cancer cascade genetic testing. Genet. Med. 22, 719\u2013726 (2020).","journal-title":"Genet. Med."},{"key":"1024_CR143","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","volume":"11","author":"SM Teutsch","year":"2009","unstructured":"Teutsch, S. M. et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet. Med. 11, 3\u201314 (2009).","journal-title":"Genet. Med."},{"key":"1024_CR144","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41525-019-0096-5","volume":"4","author":"E Courtney","year":"2019","unstructured":"Courtney, E. et al. Impact of free cancer predisposition cascade genetic testing on uptake in Singapore. NPJ Genom. Med. 4, 22 (2019).","journal-title":"NPJ Genom. Med."},{"key":"1024_CR145","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41431-020-00725-5","volume":"28","author":"S Srinivasan","year":"2020","unstructured":"Srinivasan, S., Won, N. Y., Dotson, W. D., Wright, S. T. & Roberts, M. C. Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur. J. Hum. Genet. 28, 1631\u20131644 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"1024_CR146","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1377\/hlthaff.2017.1630","volume":"37","author":"MC Roberts","year":"2018","unstructured":"Roberts, M. C. et al. Delivery of cascade screening for hereditary conditions: a scoping review of the literature. Health Aff. 37, 801\u2013808 (2018).","journal-title":"Health Aff."},{"key":"1024_CR147","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/thy.2008.0403","volume":"19","author":"American Thyroid Association Guidelines Task Force.","year":"2009","unstructured":"American Thyroid Association Guidelines Task Force. et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565\u2013612 (2009).","journal-title":"Thyroid"},{"key":"1024_CR148","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","volume":"23","author":"SP Rednam","year":"2017","unstructured":"Rednam, S. P. et al. Von Hippel\u2013Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin. Cancer Res. 23, e68\u2013e75 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1024_CR149","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot, S. et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 98, 4006\u20134012 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR150","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","volume":"169","author":"C Pamporaki","year":"2022","unstructured":"Pamporaki, C. et al. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. Eur. J. Cancer 169, 32\u201341 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1024_CR151","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"Roman-Gonzalez, A. et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann. Surg. 268, 172\u2013178 (2018).","journal-title":"Ann. Surg."},{"key":"1024_CR152","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","volume":"24","author":"V Strajina","year":"2017","unstructured":"Strajina, V. et al. Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series. Ann. Surg. Oncol. 24, 1546\u20131550 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"1024_CR153","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0022-5347(17)61732-4","volume":"104","author":"MA Immergut","year":"1970","unstructured":"Immergut, M. A., Boldus, R., K\u00f6llin, C. P. & Rohlf, P. The management of ectopic pheochromocytoma producing ureteral obstruction. J. Urol. 104, 337\u2013341 (1970).","journal-title":"J. Urol."},{"key":"1024_CR154","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/BF03218106","volume":"48","author":"K Nonaka","year":"2000","unstructured":"Nonaka, K., Makuuchi, H., Naruse, Y., Kobayashi, T. & Goto, M. Surgical excision of malignant pheochromocytoma in the left atrium. Jpn J. Thorac. Cardiovasc. Surg. 48, 126\u2013128 (2000).","journal-title":"Jpn J. Thorac. Cardiovasc. Surg."},{"key":"1024_CR155","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","volume":"45","author":"Y Ohshima","year":"2018","unstructured":"Ohshima, Y. et al. Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur. J. Nucl. Med. Mol. Imaging 45, 999\u20131010 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1024_CR156","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala\u2010Ramirez","year":"2012","unstructured":"Ayala\u2010Ramirez, M. et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra\u2010adrenal paragangliomas. Cancer 118, 2804\u20132812 (2012).","journal-title":"Cancer"},{"key":"1024_CR157","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","volume":"115","author":"K Nastos","year":"2017","unstructured":"Nastos, K. et al. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas. J. Surg. Oncol. 115, 425\u2013434 (2017).","journal-title":"J. Surg. Oncol."},{"key":"1024_CR158","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/BF03348026","volume":"20","author":"K-C Loh","year":"1997","unstructured":"Loh, K.-C., Fitzgerald, P. A., Matthay, K. K., Yeo, P. P. B. & Price, D. C. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J. Endocrinol. Invest. 20, 648\u2013658 (1997).","journal-title":"J. Endocrinol. Invest."},{"key":"1024_CR159","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1210\/clinem\/dgz074","volume":"105","author":"MP Thorpe","year":"2020","unstructured":"Thorpe, M. P. et al. Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG. J. Clin. Endocrinol. Metab. 105, e494\u2013e501 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43880-6","volume":"9","author":"H Wakabayashi","year":"2019","unstructured":"Wakabayashi, H. et al. A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci. Rep. 9, 7625 (2019).","journal-title":"Sci. Rep."},{"key":"1024_CR161","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn, L. T., Niemeijer, N. D., Dekkers, O. M. & Corssmit, E. P. M. 131I\u2010MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta\u2010analysis. Clin. Endocrinol. 80, 487\u2013501 (2014).","journal-title":"Clin. Endocrinol."},{"key":"1024_CR162","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma, D. A. et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J. Nucl. Med. 60, 623\u2013630 (2019).","journal-title":"J. Nucl. Med."},{"key":"1024_CR163","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1210\/jc.2017-02030","volume":"103","author":"RB Noto","year":"2018","unstructured":"Noto, R. B. et al. Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma. J. Clin. Endocrinol. Metab. 103, 213\u2013220 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR164","unstructured":"Food and Drug Administration. Highlights of prescribing information: AZEDRA (iobenguane I 131) injection, for intravenous use. FDA www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209607s000lbl.pdf (2018)."},{"key":"1024_CR165","unstructured":"US Securities and Exchange Commission. Form 8-K: Lantheus Holdings, Inc. Lantheus investor.lantheus.com\/node\/14836\/html (2023)."},{"key":"1024_CR166","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1196\/annals.1353.050","volume":"1073","author":"PA Fitzgerald","year":"2006","unstructured":"Fitzgerald, P. A. et al. Malignant pheochromocytomas and paragangliomas. Ann. N. Y. Acad. Sci. 1073, 465\u2013490 (2006).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1024_CR167","doi-asserted-by":"publisher","first-page":"15879","DOI":"10.1073\/pnas.0907843106","volume":"106","author":"CG Ziegler","year":"2009","unstructured":"Ziegler, C. G. et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc. Natl Acad. Sci. 106, 15879\u201315884 (2009).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1024_CR168","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/02841860701441848","volume":"46","author":"M Van Essen","year":"2007","unstructured":"Van Essen, M., Krenning, E. P., De Jong, M., Valkema, R. & Kwekkeboom, D. J. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 46, 723\u2013734 (2007).","journal-title":"Acta Oncol."},{"key":"1024_CR169","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29056","volume":"68","author":"JH Foster","year":"2021","unstructured":"Foster, J. H. et al. Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. Pediatr. Blood Cancer 68, e29056 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR170","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR171","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2016.07.017","volume":"66","author":"KE Huibregtse","year":"2016","unstructured":"Huibregtse, K. E. et al. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine. Eur. J. Cancer 66, 144\u2013152 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1024_CR172","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00043426-200307000-00009","volume":"25","author":"B Weiss","year":"2003","unstructured":"Weiss, B., Vora, A., Huberty, J., Hawkins, R. A. & Matthay, K. K. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J. Pediatr. Hematol. Oncol. 25, 543\u2013547 (2003).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"1024_CR173","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","volume":"8","author":"S Asai","year":"2017","unstructured":"Asai, S., Katabami, T., Tsuiki, M., Tanaka, Y. & Naruse, M. Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Horm. Cancer 8, 108\u2013118 (2017).","journal-title":"Horm. Cancer"},{"key":"1024_CR174","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang, H. et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine. Cancer 113, 2020\u20132028 (2008).","journal-title":"Cancer"},{"key":"1024_CR175","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10571-018-0579-4","volume":"38","author":"I Jawed","year":"2018","unstructured":"Jawed, I. et al. Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy. Cell Mol. Neurobiol. 38, 1099\u20131106 (2018).","journal-title":"Cell Mol. Neurobiol."},{"key":"1024_CR176","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer, N. D., Alblas, G., van Hulsteijn, L. T., Dekkers, O. M. & Corssmit, E. P. M. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta\u2010analysis. Clin. Endocrinol. 81, 642\u2013651 (2014).","journal-title":"Clin. Endocrinol."},{"key":"1024_CR177","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch, S. D. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med. 109, 267\u2013273 (1988).","journal-title":"Ann. Intern. Med."},{"key":"1024_CR178","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe, A. et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm. Cancer 4, 103\u2013110 (2013).","journal-title":"Horm. Cancer"},{"key":"1024_CR179","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40272-017-0251-3","volume":"19","author":"F Berthold","year":"2017","unstructured":"Berthold, F., Spix, C., Kaatsch, P. & Lampert, F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979\u20132015. Pediatr. Drugs 19, 577\u2013593 (2017).","journal-title":"Pediatr. Drugs"},{"key":"1024_CR180","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.3747\/co.v18i1.675","volume":"18","author":"U Bartels","year":"2011","unstructured":"Bartels, U. et al. The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium. Curr. Oncol. 18, e19\u2013e24 (2011).","journal-title":"Curr. Oncol."},{"key":"1024_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1066208","volume":"13","author":"C Urquhart","year":"2022","unstructured":"Urquhart, C. et al. The use of temozolomide in paediatric metastatic phaeochromocytoma\/paraganglioma: a case report and literature review. Front. Endocrinol. 13, 1066208 (2022).","journal-title":"Front. Endocrinol."},{"key":"1024_CR182","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/ERC-21-0392","volume":"29","author":"K Perez","year":"2022","unstructured":"Perez, K. et al. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 29, 533\u2013544 (2022).","journal-title":"Endocr. Relat. Cancer"},{"key":"1024_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26314","volume":"64","author":"S Sait","year":"2017","unstructured":"Sait, S., Kobos, R., LaQuaglia, M. P., Pandit\u2010Taskar, N. & Modak, S. Acute myeloid leukemia therapy elicits durable complete response in chemoradio\u2010resistant metastatic paraganglioma. Pediatr. Blood Cancer 64, e26314 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR184","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30020","volume":"70","author":"C Singh","year":"2023","unstructured":"Singh, C., Bindra, R. S., Glazer, P. M., Vasquez, J. C. & Pashankar, F. Metastatic and multiply relapsed SDH\u2010deficient GIST and paraganglioma displays clinical response to combined poly ADP\u2010ribose polymerase inhibition and temozolomide. Pediatr. Blood Cancer 70, e30020 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR185","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane, G. M. et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br. J. Cancer 120, 1113\u20131119 (2019).","journal-title":"Br. J. Cancer"},{"key":"1024_CR186","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.3390\/ijms21124469","volume":"21","author":"F Carofiglio","year":"2020","unstructured":"Carofiglio, F. et al. Bcr-Abl tyrosine kinase inhibitors in the treatment of pediatric CML. Int. J. Mol. Sci. 21, 4469 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1024_CR187","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042814","volume":"11","author":"M Chen","year":"2021","unstructured":"Chen, M., Zhu, Y., Lin, Y., Tengwang, T. & Zhang, L. Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. BMJ Open. 11, e042814 (2021).","journal-title":"BMJ Open."},{"key":"1024_CR188","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/1871525719666211214114229","volume":"20","author":"A Tragiannidis","year":"2022","unstructured":"Tragiannidis, A. & Mantadakis, E. Effects of tyrosine kinase inhibitors on growth and bone metabolism in children with haematologic malignancies. Cardiovasc. Hematol. Agents Med. Chem. 20, 175\u2013177 (2022).","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"1024_CR189","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","volume":"385","author":"J Kamihara","year":"2021","unstructured":"Kamihara, J. et al. Belzutifan, a potent HIF2\u03b1 Inhibitor, in the Pacak\u2013Zhuang syndrome. N. Engl. J. Med. 385, 2059\u20132065 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR190","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1210\/endrev\/bnac025","volume":"44","author":"RA Toledo","year":"2023","unstructured":"Toledo, R. A. et al. Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia. Endocr. Rev. 44, 312\u2013322 (2023).","journal-title":"Endocr. Rev."},{"key":"1024_CR191","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.3390\/ijms222112089","volume":"22","author":"A Kaczmarska","year":"2021","unstructured":"Kaczmarska, A., \u015aliwa, P., Lejman, M. & Zawitkowska, J. The use of inhibitors of tyrosine kinase in paediatric haemato-oncology \u2013 when and why? Int. J. Mol. Sci. 22, 12089 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1024_CR192","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.jvir.2009.07.031","volume":"20","author":"AM Venkatesan","year":"2009","unstructured":"Venkatesan, A. M. et al. Radiofrequency ablation of metastatic pheochromocytoma. J. Vasc. Interv. Radiol. 20, 1483\u20131490 (2009).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1024_CR193","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jvir.2011.06.016","volume":"22","author":"JF McBride","year":"2011","unstructured":"McBride, J. F. et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J. Vasc. Interv. Radiol. 22, 1263\u20131270 (2011).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1024_CR194","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jnci\/93.8.648","volume":"93","author":"K Pacak","year":"2001","unstructured":"Pacak, K. et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J. Natl Cancer Inst. 93, 648\u2013649 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"1024_CR195","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","volume":"59","author":"G Gravel","year":"2018","unstructured":"Gravel, G. et al. Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine 59, 547\u2013554 (2018).","journal-title":"Endocrine"},{"key":"1024_CR196","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jvir.2009.01.031","volume":"20","author":"MD Mamlouk","year":"2009","unstructured":"Mamlouk, M. D., vanSonnenberg, E., Stringfellow, G., Smith, D. & Wendt, A. Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers. J. Vasc. Interv. Radiol. 20, 670\u2013673 (2009).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1024_CR197","first-page":"2149","volume":"29","author":"S Ohkawa","year":"2002","unstructured":"Ohkawa, S. et al. Examination of percutaneous microwave coagulation and radiofrequency ablation therapy for metastatic liver cancer [Japanese]. Gan To Kagaku Ryoho 29, 2149\u20132151 (2002).","journal-title":"Gan To Kagaku Ryoho"},{"key":"1024_CR198","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ejso.2004.03.010","volume":"30","author":"J Tepel","year":"2004","unstructured":"Tepel, J., Hinz, S., Klomp, H.-J., Kapischke, M. & Kremer, B. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. Eur. J. Surg. Oncol. 30, 551\u2013555 (2004).","journal-title":"Eur. J. Surg. Oncol."},{"key":"1024_CR199","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cancers11020195","volume":"11","author":"J Kohlenberg","year":"2019","unstructured":"Kohlenberg, J. et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers 11, 195 (2019).","journal-title":"Cancers"},{"key":"1024_CR200","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ijri.IJRI_260_16","volume":"27","author":"A Chahal","year":"2017","unstructured":"Chahal, A. et al. CT-guided percutaneous radiofrequency ablation of osteoid osteoma: our experience in 87 patients. Indian. J. Radiol. Imaging 27, 207\u2013215 (2017).","journal-title":"Indian. J. Radiol. Imaging"},{"key":"1024_CR201","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1602400326","volume":"24","author":"Y Ar\u0131kan","year":"2016","unstructured":"Ar\u0131kan, Y. et al. Percutaneous radiofrequency ablation for osteoid osteoma under guidance of three-dimensional fluoroscopy. J. Orthop. Surg. 24, 398\u2013402 (2016).","journal-title":"J. Orthop. Surg."},{"key":"1024_CR202","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3747\/co.v17i1.460","volume":"17","author":"TL Tucker","year":"2010","unstructured":"Tucker, T. L., Samant, R. S. & Fitzgibbon, E. J. Knowledge and utilization of palliative radiotherapy by pediatric oncologists. Curr. Oncol. 17, 48\u201355 (2010).","journal-title":"Curr. Oncol."},{"key":"1024_CR203","doi-asserted-by":"publisher","first-page":"S829","DOI":"10.1002\/pbc.25695","volume":"62","author":"MS Weaver","year":"2015","unstructured":"Weaver, M. S. et al. Palliative care as a standard of care in pediatric oncology. Pediatr. Blood Cancer 62, S829\u2013S833 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR204","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26589","volume":"64","author":"AD Rao","year":"2017","unstructured":"Rao, A. D. et al. Practice patterns of palliative radiation therapy in pediatric oncology patients in an international pediatric research consortium. Pediatr. Blood Cancer 64, e26589 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR205","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/jnci\/dji139","volume":"97","author":"WF Hartsell","year":"2005","unstructured":"Hartsell, W. F. et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst. 97, 798\u2013804 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"1024_CR206","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","volume":"25","author":"E Chow","year":"2007","unstructured":"Chow, E., Harris, K., Fan, G., Tsao, M. & Sze, W. M. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol. 25, 1423\u20131436 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR207","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz, S. et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract. Radiat. Oncol. 7, 4\u201312 (2017).","journal-title":"Pract. Radiat. Oncol."},{"key":"1024_CR208","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0032-1308992","volume":"44","author":"L Fishbein","year":"2012","unstructured":"Fishbein, L. et al. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Horm. Metab. Res. 44, 405\u2013410 (2012).","journal-title":"Horm. Metab. Res."},{"key":"1024_CR209","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40618-022-01908-1","volume":"46","author":"Z Gu","year":"2022","unstructured":"Gu, Z. et al. Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy. J. Endocrinol. Invest. 46, 477\u2013485 (2022).","journal-title":"J. Endocrinol. Invest."},{"key":"1024_CR210","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fonc.2014.00166","volume":"4","author":"J Vogel","year":"2014","unstructured":"Vogel, J. et al. External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. Front. Oncol. 4, 166 (2014).","journal-title":"Front. Oncol."},{"key":"1024_CR211","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2018","unstructured":"Breen, W. et al. External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv. Radiat. Oncol. 3, 25\u201329 (2018).","journal-title":"Adv. Radiat. Oncol."},{"key":"1024_CR212","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez, M. et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J. Clin. Endocrinol. Metab. 98, 1492\u20131497 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1024_CR213","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/00006231-200207000-00011","volume":"23","author":"C Okuyama","year":"2002","unstructured":"Okuyama, C. et al. Utility of follow-up studies using meta-[123I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl. Med. Commun. 23, 663\u2013672 (2002).","journal-title":"Nucl. Med. Commun."},{"key":"1024_CR214","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/BF00941848","volume":"22","author":"NL Hadj-Djilani","year":"1995","unstructured":"Hadj-Djilani, N. L., Lebtahi, N.-E., Bischof Delaloye, A., Laurini, R. & Beck, D. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur. J. Nucl. Med. 22, 322\u2013329 (1995).","journal-title":"Eur. J. Nucl. Med."},{"key":"1024_CR215","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.2008.17.6107","volume":"27","author":"BH Kushner","year":"2009","unstructured":"Kushner, B. H., Kramer, K., Modak, S. & Cheung, N.-K. V. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J. Clin. Oncol. 27, 1041\u20131046 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR216","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1200\/JCO.2009.24.0036","volume":"27","author":"K Satharasinghe","year":"2009","unstructured":"Satharasinghe, K. et al. False-positive MIBG scans with normal computed tomography imaging in patients with high-risk neuroblastoma. J. Clin. Oncol. 27, e233\u2013e234 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR217","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah, M. H. et al. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and adrenal tumors, version 2.2021. J. Natl Compr. Cancer Netw. 19, 839\u2013868 (2021).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1024_CR218","doi-asserted-by":"publisher","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","volume":"23","author":"A Berruti","year":"2012","unstructured":"Berruti, A. et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii131\u2013vii138 (2012).","journal-title":"Ann. Oncol."},{"key":"1024_CR219","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jpainsymman.2017.09.022","volume":"55","author":"A Coughtrey","year":"2018","unstructured":"Coughtrey, A. et al. The effectiveness of psychosocial interventions for psychological outcomes in pediatric oncology: a systematic review. J. Pain. Symptom Manag. 55, 1004\u20131017 (2018).","journal-title":"J. Pain. Symptom Manag."},{"key":"1024_CR220","doi-asserted-by":"publisher","first-page":"101734","DOI":"10.1016\/j.eclinm.2022.101734","volume":"55","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Sundquist, J., Sundquist, K., Zheng, D. & Ji, J. Mental health outcomes in parents of children with a cancer diagnosis in Sweden: a nationwide cohort study. EClinicalMedicine 55, 101734 (2023).","journal-title":"EClinicalMedicine"},{"key":"1024_CR221","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1043454206298695","volume":"24","author":"T Malbasa","year":"2007","unstructured":"Malbasa, T., Kodish, E. & Santacroce, S. J. Adolescent adherence to oral therapy for leukemia: a focus group study. J. Pediatr. Oncol. Nurs. 24, 139\u2013151 (2007).","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"1024_CR222","doi-asserted-by":"publisher","first-page":"S419","DOI":"10.1002\/pbc.25675","volume":"62","author":"L Wiener","year":"2015","unstructured":"Wiener, L., Kazak, A. E., Noll, R. B., Patenaude, A. F. & Kupst, M. J. Standards for the psychosocial care of children with cancer and their families: an introduction to the special issue. Pediatr. Blood Cancer 62, S419\u2013S424 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"1024_CR223","unstructured":"SIOP Europe. Standards of care for children with cancer. SIOPE siope.eu\/european-research-and-standards\/standards-of-care-in-paediatric-oncology\/ (2009)."},{"key":"1024_CR224","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/pon.1473","volume":"18","author":"DCM Seitz","year":"2009","unstructured":"Seitz, D. C. M., Besier, T. & Goldbeck, L. Psychosocial interventions for adolescent cancer patients: a systematic review of the literature. Psychooncology 18, 683\u2013690 (2009).","journal-title":"Psychooncology"},{"key":"1024_CR225","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/88.12.812","volume":"88","author":"HA Tejeda","year":"1996","unstructured":"Tejeda, H. A. et al. Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment trials. J. Natl Cancer Inst. 88, 812\u2013816 (1996).","journal-title":"J. Natl Cancer Inst."},{"key":"1024_CR226","first-page":"148","volume":"11","author":"MC Bond","year":"2006","unstructured":"Bond, M. C. & Pritchard, S. Understanding clinical trials in childhood cancer. Paediatr. Child. Health 11, 148\u2013150 (2006).","journal-title":"Paediatr. Child. Health"},{"key":"1024_CR227","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger, S. P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 1663\u20131669 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1024_CR228","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(18)30761-7","volume":"20","author":"N Bhakta","year":"2019","unstructured":"Bhakta, N. et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 20, e42\u2013e53 (2019).","journal-title":"Lancet Oncol."},{"key":"1024_CR229","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_156686","volume":"35","author":"JM Unger","year":"2016","unstructured":"Unger, J. M., Cook, E., Tai, E. & Bleyer, A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am. Soc. Clin. Oncol. Educ. Book 35, 185\u2013198 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1024_CR230","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/PPO.0b013e3181ff6509","volume":"16","author":"WA Bleyer","year":"2010","unstructured":"Bleyer, W. A. Potential favorable impact of the Affordable Care Act of 2010 on cancer in young adults in the United States. Cancer J. 16, 563\u2013571 (2010).","journal-title":"Cancer J."},{"key":"1024_CR231","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.seminoncol.2020.02.006","volume":"47","author":"A Major","year":"2020","unstructured":"Major, A., Cox, S. M. & Volchenboum, S. L. Using big data in pediatric oncology: current applications and future directions. Semin. Oncol. 47, 56\u201364 (2020).","journal-title":"Semin. Oncol."},{"key":"1024_CR232","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"Wells, S. A. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567\u2013610 (2015).","journal-title":"Thyroid"}],"updated-by":[{"DOI":"10.1038\/s41574-025-01167-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000}},{"DOI":"10.1038\/s41574-024-01034-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000}}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01024-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:28:28Z","timestamp":1757118508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01024-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":232,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1038\/s41574-024-01024-5","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"17 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41574-025-01167-z","URL":"https:\/\/doi.org\/10.1038\/s41574-025-01167-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41574-024-01034-3","URL":"https:\/\/doi.org\/10.1038\/s41574-024-01034-3","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.T.C. has received a Novartis speaker honorarium and is in an editorial position in\n                      Clinical Endocrinology\n                      . C.J. has received funding to his institution from Lantheus, Progenics, Exelixis, Merck Sharpe and Dohme and is a clinical adviser for Lantheus and Merck Sharpe and Dohme. S.D.M. is the Director of the NIHR Clinical Research Facility at Great Ormond Street Hospital, London. D.T. has received speaker and attendance honoraria from AAA\/NOVARTIS. D.T. is a cofounder, stakeholder, and the chief medical officer (CMO) of SILON Therapeutics, without receiving personal payments. M.F. is an unpaid member of the ExCo of the European Society of Endocrinology. J.W.M.L. is an unpaid member of the advisory board of the Phaeochromocytoma and Paraganglioma Alliance.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}